/SGHT
SGHT Stock - Sight Sciences, Inc.
Healthcare|Medical - DevicesNASDAQ
$8.45+2.30%
+$0.19 (+2.30%) • Dec 19
62
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).63
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.24
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+6.5%upside
Target: $9.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SGHT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$8.37 – $8.53
TARGET (TP)$9.00
STOP LOSS$7.77
RISK/REWARD1:0.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.41
52W High$8.80
52W Low$2.03
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $79.87M | $81.06M | $71.33M | $48.96M | $27.64M |
| Gross Profit | $68.28M | $69.17M | $58.97M | $40.35M | $18.43M |
| Gross Margin | 85.5% | 85.3% | 82.7% | 82.4% | 66.7% |
| Operating Income | $-50,532,000 | $-57,274,000 | $-83,954,000 | $-51,478,000 | $-32,188,000 |
| Net Income | $-51,507,000 | $-55,547,000 | $-86,242,000 | $-62,960,000 | $-34,693,000 |
| Net Margin | -64.5% | -68.5% | -120.9% | -128.6% | -125.5% |
| EPS | $-1.03 | $-1.14 | $-1.80 | $-1.33 | $-0.74 |
Company Overview
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
36%
Hold / Neutral
6
55%
Sell / Underperform
1
9%
Analyst Consensus🔴 Bearish
4 Bullish7 Neutral/Bearish
Price Targets
$8
Average Target
↓ 7.8% Downside
Now
$5
Low
$8
Average
$15
High
Based on 10 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 8th 2025 | Lake Street | Upgrade | Buy | $5 |
| December 6th 2024 | UBS | Initiation | Buy | $5.5 |
| November 4th 2024 | Lake Street | Downgrade | Hold | $5← $10 |
| August 21st 2024 | Lake Street | Initiation | Buy | $10 |
| September 12th 2023 | BofA Securities | Downgrade | Underperform | $4.5← $10 |
| September 12th 2023 | Piper Sandler | Downgrade | Neutral | $5.5← $15 |
| September 12th 2023 | William Blair | Downgrade | Market Perform | - |
| August 24th 2023 | Morgan Stanley | Downgrade | Equal Weight | $8.4← $12 |
| July 10th 2023 | Citigroup | Downgrade | Neutral | $9← $15 |
| January 6th 2023 | Stifel | Upgrade | Buy | $15← $10 |
| October 4th 2022 | Needham | Initiation | Hold | - |
| July 26th 2022 | Stifel | Initiation | Hold | $10 |
Earnings History & Surprises
SGHTBeat Rate
67%
Last 18 quarters
Avg Surprise
+1.4%
EPS vs Estimate
Beats / Misses
12/6
Last 12 quarters
Latest EPS
$-0.16
Q4 2025
EPS Surprise History
Q1 24
+37.1%
$-0.22vs$-0.35
Q2 24
-13.8%
$-0.33vs$-0.29
Q3 24
+19.4%
$-0.25vs$-0.31
Q4 24
+4.3%
$-0.22vs$-0.23
Q1 25
-4.5%
$-0.23vs$-0.22
Q2 25
+3.4%
$-0.28vs$-0.29
Q3 25
+8.0%
$-0.23vs$-0.25
Q4 25
+38.5%
$-0.16vs$-0.26
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 4, 2026 | $-0.17 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.26 | $-0.16 | +38.5% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.25 | $-0.23 | +8.0% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.29 | $-0.28 | +3.4% | ✓ BEAT |
Q1 2025 | Mar 5, 2025 | $-0.22 | $-0.23 | -4.5% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.23 | $-0.22 | +4.3% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $-0.31 | $-0.25 | +19.4% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $-0.29 | $-0.33 | -13.8% | ✗ MISS |
Q1 2024 | Mar 7, 2024 | $-0.35 | $-0.22 | +37.1% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-0.31 | $-0.27 | +12.9% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.35 | $-0.30 | +14.3% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-0.41 | $-0.35 | +14.6% | ✓ BEAT |
Q1 2023 | Mar 13, 2023 | $-0.42 | $-0.35 | +16.7% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.47 | $-0.46 | +2.1% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.46 | $-0.50 | -8.7% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-0.41 | $-0.49 | -19.5% | ✗ MISS |
Q1 2022 | Mar 24, 2022 | $-0.38 | $-0.34 | +10.5% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.38 | $-0.43 | -13.2% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-0.93 | $-1.83 | -96.8% | ✗ MISS |
Latest News
Citigroup Maintains Neutral on Sight Sciences, Raises Price Target to $9.1
➖ NeutralBenzinga•Dec 11, 2025, 09:05 PM•Also:
Morgan Stanley Maintains Equal-Weight on Sight Sciences, Raises Price Target to $8
➖ NeutralBenzinga•Dec 2, 2025, 05:55 PM
Sight Sciences Reports Peer-Reviewed Studies Showing OMNI Surgical System With TruSync Reduces IOP And Medication Use In Cataract-Combination, Standalone, And African American Patients
📈 PositiveBenzinga•Nov 11, 2025, 12:18 PM
Morgan Stanley Maintains Equal-Weight on Sight Sciences, Raises Price Target to $6
➖ NeutralBenzinga•Nov 10, 2025, 06:13 PM
Sight Sciences shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates.
📈 PositiveBenzinga•Nov 7, 2025, 04:19 PM
Piper Sandler Maintains Neutral on Sight Sciences, Raises Price Target to $5
➖ NeutralBenzinga•Nov 7, 2025, 12:47 PM
Sight Sciences Raises FY2025 Sales Guidance from $72.000M-$76.000M to $76.000M-$78.000M vs $74.019M Est
📈 PositiveBenzinga•Nov 6, 2025, 09:07 PM
Sight Sciences Q3 EPS $(0.16) Beats $(0.28) Estimate, Sales $19.906M Beat $17.744M Estimate
📈 PositiveBenzinga•Nov 6, 2025, 09:07 PM
Sight Sciences Appoints James Rodberg As CFO, Alison Bauerlein As Chief Operating Officer, Effective Nov. 5, 2025
➖ NeutralBenzinga•Nov 6, 2025, 09:05 PM
Lake Street Maintains Buy on Sight Sciences, Raises Price Target to $7
📈 PositiveBenzinga•Oct 21, 2025, 02:56 PM
Sight Sciences shares are trading higher after the company entered into a share sale and purchase agreement to acquire 104,000 shares of LPW Electronics from the company's chairman for ~$730,000.
📈 PositiveBenzinga•Oct 17, 2025, 05:33 PM
Sight Sciences shares are trading higher after the company announced that it secured medicare pricing for its TearCare eyelid treatment.
📈 PositiveBenzinga•Oct 17, 2025, 02:21 PM
Sight Sciences Secures Medicare Pricing For TearCare Eyelid Treatment, Expanding Coverage Across Novitas And First Coast Jurisdictions
📈 PositiveBenzinga•Oct 17, 2025, 11:03 AM
Citigroup Maintains Neutral on Sight Sciences, Lowers Price Target to $4
➖ NeutralBenzinga•Oct 7, 2025, 05:48 PM•Also:
Sight Sciences Highlights Meta-Analysis Of 2,379 Eyes Showing OMNI Delivers Sustained IOP Reductions And Medication-Free Outcomes
📈 PositiveBenzinga•Sep 17, 2025, 11:11 AM•Also:
Sight Sciences' OMNI Surgical System To Be Included In UnitedHealthcare's Expanded Coverage Of Glaucoma Surgical Treatments
📈 PositiveBenzinga•Sep 9, 2025, 11:07 AM•Also:
Sight Sciences Publishes Dry Eye Workshop III Report From Tear Film And Ocular Surface Society In American Journal of Ophthalmology
➖ NeutralBenzinga•Sep 2, 2025, 08:07 PM
Needham Reiterates Hold on Sight Sciencesto Hold
➖ NeutralBenzinga•Aug 28, 2025, 04:44 PM
Sight Sciences Inc To Cut 20% Of Global Workforce; Expects $2.7-$3.0M Restructuring Charge; Reaffirms 2025 Revenue Guidance Of $72M-$76M; Estimates $11.9M Annual Savings From Workforce Reductions; Matthew Link To Step Down As CCO
📉 NegativeBenzinga•Aug 27, 2025, 08:57 PM
Citigroup Maintains Neutral on Sight Sciences, Raises Price Target to $4.5
➖ NeutralBenzinga•Aug 21, 2025, 06:14 PM•Also:
Frequently Asked Questions about SGHT
What is SGHT's current stock price?
Sight Sciences, Inc. (SGHT) is currently trading at $8.45 per share. The stock has moved +2.30% today.
What is the analyst price target for SGHT?
The average analyst price target for SGHT is $9.00, based on 1 analyst.
What sector is Sight Sciences, Inc. in?
Sight Sciences, Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is SGHT's market cap?
Sight Sciences, Inc. has a market capitalization of $0.45 billion, making it a small-cap company.
Does SGHT pay dividends?
No, Sight Sciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCERS
Cerus Corporation
$2.09
Mkt Cap: $0.4B
CVRX
CVRx, Inc.
$8.03
Mkt Cap: $0.2B
LFCR
Lifecore Biomedical, Inc.
$8.04
Mkt Cap: $0.3B
MASS
908 Devices Inc.
$5.84
Mkt Cap: $0.2B
OMI
Owens & Minor, Inc.
$2.84
Mkt Cap: $0.2B
PRQR
ProQR Therapeutics N.V.
$2.21
Mkt Cap: $0.2B
QTRX
Quanterix Corporation
$6.59
Mkt Cap: $0.3B
SENS
Senseonics Holdings, Inc.
$6.15
Mkt Cap: $0.3B
SNWV
SANUWAVE Health, Inc.
$32.25
Mkt Cap: $0.3B
VMD
Viemed Healthcare, Inc.
$7.42
Mkt Cap: $0.3B
Explore stocks similar to SGHT for comparison